Advanced Enzyme Technologies (ADVENZYMES) Q4 25/26 earnings summary

Executive summary

• Achieved record quarterly and annual revenue for FY 2026, with strong growth across all business divisions and segments, despite global supply chain disruptions and inflationary pressures.

• Approved audited standalone and consolidated financial results for the year ended March 31, 2026, and the fourth quarter results.

• Maintained consistent supply and operational performance, leveraging R&D investments and regulatory filings to support future growth.

• Focused on broad-based, long-term growth through innovation, capacity expansion, and entry into new geographies.

• Board approved re-appointment of Mr. Mukund Kabra as Whole Time Director and appointment of Mr. Pradip Shah as Independent Director, both subject to AGM approval.

Financial highlights

• Q4 FY26 revenue: ₹2,034 million (+22% y-o-y, +18% q-o-q); EBITDA: ₹632 million (+39% y-o-y, +28% q-o-q); PAT: ₹453 million (+69% y-o-y, +5% q-o-q).

• FY26 revenue: ₹7,458 million (+17% y-o-y); EBITDA: ₹2,291 million (+18% y-o-y); PAT: ₹1,736 million (+30% y-o-y).

• Consolidated net profit for FY 2025-26 was ₹2,684.19 million, compared to ₹1,527.96 million in the previous year.

• EPS for FY26: ₹15.08, up 29% year-over-year.

• Net worth at FY26: ₹16,320 million.

Outlook and guidance

• Management expects steady momentum to continue, targeting double-digit growth, with margin stability anticipated despite inflationary pressures.

• Focus on expanding product portfolio in animal nutrition, probiotics, and bio-catalysis, and broadening geographical presence, especially in USA, MENA, and Asia.

• R&D center in Nashik to become operational in H2 FY 2027, supporting new product launches and innovation.

• Board intends to preserve capital for flexibility in evaluating strategic opportunities.

• Final dividend of ₹1.35 per share proposed, with payment after AGM approval.